Side-by-side financials for DMAC and LLY. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | DMAC | LLY |
|---|---|---|
| Market cap | - | $1.072 T |
| US-listed rank | - | #11 |
| Revenue (latest FY) | $500.00K | $65.18B |
| Net income (latest FY) | -$32.77M | $20.64B |
| Net margin | -6553.2% | 31.7% |
| P/E (trailing FY) | - | 51.9 |
| SEC filings | 414 | 989 |
Full pages: DiaMedica Therapeutics Inc. and ELI LILLY & Co, or browse the full rankings.